October 2, 2025JAMA Network OpenOpen Access

Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer

View Full Paper

Ask AI

Bookmark

Overall survival was similar between gemcitabine and cisplatin with and without polymeric micellar paclitaxel.
The median overall survival was 12.0 months with polymeric micellar paclitaxel and 11.1 months with standard chemotherapy.
This randomized clinical trial involved 150 patients across South Korea, showing no significant benefits from the treatment combination.
Findings highlight the limitations of adding taxanes to existing regimens for advanced biliary tract cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized clinical trial found no improvement in overall survival in advanced biliary tract cancer with polymeric micellar paclitaxel, suggesting limitations of intensified chemotherapy.

Cite This Study

Jeong et al. (2025) studied this question.

synapsesocial.com/papers/68de5d9c83cbc991d0a20465 https://doi.org/10.1001/jamanetworkopen.2025.34560

View Full Paper

Ask AI

Bookmark

Implication

Randomized clinical trial found no improvement in overall survival in advanced biliary tract cancer with polymeric micellar paclitaxel, suggesting limitations of intensified chemotherapy.

Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer

Key Points

Discussion

Implication

Cite This Study

Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading